What's coming next
Every trial result still to come, soonest first.
Facts on this page checked 18–22 Oct 2026
This page lists every trial in people with a result still to come. It covers all six approaches. It also covers trials that try to prevent Parkinson's in people at high risk.
Each trial says what it will tell us and who it is for. Most of these trials ask whether a drug is safe, or whether it reaches its target in the body. Only large, late trials can show whether a treatment slows Parkinson's. They are marked Phase 3.
At a glance
- Results due
- 28 trials
- Next result
- Nov 2026 · Idebenone
- Final large trials
- 4 Phase 3 trials: exPDite-2 (Mar 2027), BHV-8000 (Aug 2027), ASPro-PD (Feb 2029), PARAISO (Jun 2029)
- Largest trial
- PARAISO, 900 people, Jun 2029
Dates are expected, not promised. Trials often report late.
Expected in 2026
-
Idebenone · a prevention trial
Result due Nov 2026
Tests whether idebenone delays Parkinson's in people with a sleep disorder that often comes first. The registry lists 28 people against 142 planned, so it may be too small to give a clear answer.
Who: Adults with REM sleep behaviour disorder, in Shanghai. No longer recruiting. · Last checked 22 Oct 2026
Part of: Preventing Parkinson's in people at risk
Details and sources: Idebenone Check if it is recruiting: Idebenone
-
TB006 · an antibody drug aimed at inflammation
Result due Nov 2026
Will tell us, early on, whether an antibody against galectin-3 changes symptom scores compared with placebo. It cannot prove slowing.
Who: People aged 50 to 80 with early Parkinson's; enrolment is closed · Last checked 19 Oct 2026
Part of: Look beyond the brain
-
Low-dose lithium · a small study in Buffalo, USA
Result due Nov 2026
Small studies of 15 to 35 people that measure blood and scan markers. They cannot show whether lithium slows Parkinson's.
Who: People with Parkinson's, in small studies · Last checked 22 Oct 2026
Part of: Keep vulnerable cells alive
Details and sources: Low-dose lithium Check if it is recruiting: Low-dose lithium
-
EXIST · exidavnemab, an antibody drug
Result due Dec 2026
A safety study that finished in August 2026. It checks safety, not whether the drug slows Parkinson's.
Who: People with Parkinson's or MSA · Last checked 19 Oct 2026
Part of: Clear the bad protein
-
N-DOSE · nicotinamide riboside, a form of vitamin B3, at three doses
Result due Dec 2026
Will tell us which dose raises brain NAD most reliably. It cannot show slowing. It finished in April 2025 and no result has been found.
Who: Adults with Parkinson's; the registry has the details · Last checked 22 Oct 2026
Part of: Help cells clean up
Details and sources: N-DOSE Check if it is recruiting: N-DOSE
Expected in 2027
-
NAC · N-acetylcysteine (NAC), a supplement that helps the body make glutathione
Result due Jan 2027
Will tell us whether a brain-scan change seen in small trials without placebo holds up. Even a good result would not show slowing.
Who: People with Parkinson's. This study plans 50 people and compares NAC with a waitlist. · Last checked 22 Oct 2026
Part of: Help cells clean up
-
ASPIRO · dopamine cell precursors made from each person's own skin cells
Result due Mar 2027
It will tell us whether grafts stay safe at one year. The first 8 people had no comparison group, so gains cannot be told from a placebo effect.
Who: Adults aged 40 to 75 with Parkinson's. Enrolment is by invitation. · Last checked 19 Oct 2026
Part of: Replace or repair what's lost
Details and sources: ASPIRO Check if it is recruiting: ASPIRO
-
exPDite-2 · bemdaneprocel, dopamine nerve cells grown from embryonic stem cells
Result due Mar 2027
The first sham-controlled test of these cells, in about 102 people. It will tell us whether they raise good on-time more than a fake operation at 78 weeks.
Who: Adults with Parkinson's. The trial is recruiting. · Last checked 18 Oct 2026
Part of: Replace or repair what's lost
Details and sources: exPDite-2 Check if it is recruiting: exPDite-2
-
BEACON · BIIB122, in people with an LRRK2 gene change
Result due Mar 2027
Will tell us whether the drug is safe in LRRK2 carriers and changes cell markers. It cannot show whether it slows Parkinson's.
Who: 50 adults with an LRRK2 gene change · Last checked 19 Oct 2026
Part of: Treat the inherited causes
Details and sources: BEACON Check if it is recruiting: BEACON
-
MOST-ABLE (Osaka) · semaglutide, a diabetes drug, as a daily tablet
Result due Mar 2027
Will tell us whether a daily semaglutide tablet slows the decline in movement in 99 people over 48 weeks, compared with placebo.
Who: People with early Parkinson's, in Japan · Last checked 19 Oct 2026
Part of: Look beyond the brain
-
Radotinib · a leukaemia drug
Result due Apr 2027
A small study in 43 people. It mainly checks safety, so it cannot show whether the drug slows Parkinson's.
Who: People with Parkinson's, in France · Last checked 22 Oct 2026
Part of: Keep vulnerable cells alive
Details and sources: Radotinib Check if it is recruiting: Radotinib
-
DAPA-PD · dapansutrile, a tablet that blocks NLRP3
Result due May 2027
Will tell us whether the tablet is safe and lowers inflammation in 36 people over six months. Too small to show slowing.
Who: People aged 50 to 80 with early Parkinson's and raised inflammation in the blood, at one site in Cambridge · Last checked 18 Oct 2026
Part of: Look beyond the brain
Details and sources: DAPA-PD Check if it is recruiting: DAPA-PD
-
BHV-8000 · a pill that calms the immune system
Result due Aug 2027
Will tell us whether an immune-calming pill delays worsening of everyday movement over 48 weeks, in 550 people.
Who: People aged 40 to 80 diagnosed within two years; smokers are not included · Last checked 19 Oct 2026
Part of: Look beyond the brain
Details and sources: BHV-8000 Check if it is recruiting: BHV-8000
-
REPLACE (Kenai) · ready-made dopamine cell precursors from donor stem cells
Result due Sep 2027
It will tell us whether this frozen donor-cell product is safe over 15 months. It has no control group, and no results exist yet.
Who: People aged 45 to 75 with Parkinson's that has no known gene cause. Enrolment is complete. · Last checked 19 Oct 2026
Part of: Replace or repair what's lost
Details and sources: REPLACE (Kenai) Check if it is recruiting: REPLACE (Kenai)
-
NOSE-PD · a nasal spray of insulin plus glutathione
Result due Nov 2027
Will tell us whether adding insulin helps thinking skills, measured by a word test at 24 weeks. It would not show slowing.
Who: People with Parkinson's. This study plans 56 people, with the spray as an add-on. · Last checked 18 Oct 2026
Part of: Help cells clean up
Details and sources: NOSE-PD Check if it is recruiting: NOSE-PD
-
NEULARK · NEU-411, a second LRRK2 blocker
Result due Dec 2027
Will tell us whether blocking LRRK2 helps when people are picked by a test, not only by diagnosis. It uses a phone-app score at one year.
Who: About 150 adults with early Parkinson's, picked by a test for LRRK2-driven disease · Last checked 18 Oct 2026
Part of: Treat the inherited causes
Details and sources: NEULARK Check if it is recruiting: NEULARK
-
Mass General own-cell trial · dopamine cell precursors made from each person's own skin cells
Result due Dec 2027
It will tell us whether repeating the 2020 one-person graft is safe in up to 8 people over 2 years. It has no control group.
Who: People aged 45 to 80, at least 5 years from first symptoms, with at least 3 hours of daily off time. · Last checked 19 Oct 2026
Part of: Replace or repair what's lost
Details and sources: Mass General own-cell trial Check if it is recruiting: Mass General own-cell trial
-
UC San Diego trial · dopamine cell precursors made from donor stem cells, the same cells as Kyoto
Result due Dec 2027
It will tell us whether Kyoto's donor cells are safe in the US and keep a stable size on MRI. It has no control group.
Who: Adults aged 40 to 75 who have had Parkinson's for at least 5 years and respond well to levodopa. · Last checked 19 Oct 2026
Part of: Replace or repair what's lost
Details and sources: UC San Diego trial Check if it is recruiting: UC San Diego trial
Expected in 2028
4 trialsVacSYn, REGENERATE-PD, TARBELA-PD, Brigham own-cell trial
-
VacSYn · ACI-7104, a vaccine
Result due Jun 2028
Everyone given the vaccine so far made antibodies. The first part checks safety; a larger second part is planned.
Who: People with early Parkinson's · Last checked 19 Oct 2026
Part of: Clear the bad protein
Details and sources: VacSYn Check if it is recruiting: VacSYn
-
REGENERATE-PD · AB-1005, a gene therapy that makes the brain produce GDNF
Result due Aug 2028
It will tell us whether this gene therapy gives more good on-time than sham surgery at 18 months. GDNF infusions improved scans but not patients.
Who: People aged 45 to 75 with moderate Parkinson's. Enrolment is closed. · Last checked 18 Oct 2026
Part of: Replace or repair what's lost
Details and sources: REGENERATE-PD Check if it is recruiting: REGENERATE-PD
-
TARBELA-PD · RO7568282, a capsule that blocks NLRP3
Result due Dec 2028
Will tell us whether the capsule delays worsening of movement in 474 people with early Parkinson's.
Who: Adults aged 40 to 85 on levodopa alone, without movement complications · Last checked 19 Oct 2026
Part of: Look beyond the brain
Details and sources: TARBELA-PD Check if it is recruiting: TARBELA-PD
-
Brigham own-cell trial · dopamine nerve cells made from each person's own blood cells
Result due Dec 2028
It will tell us whether grafts are safe at 12 and 18 months. With no control group, it cannot show benefit.
Who: Adults aged 55 to 80 who have had Parkinson's for at least 5 years, respond well to levodopa and have had no brain surgery. Enrolment is by invitation. · Last checked 19 Oct 2026
Part of: Replace or repair what's lost
Details and sources: Brigham own-cell trial Check if it is recruiting: Brigham own-cell trial
Expected in 2029
4 trialsASPro-PD, PARAISO, ALN-SNCA, PRISMS
-
ASPro-PD · ambroxol, a cough medicine
Result due Feb 2029
Will tell us whether ambroxol slows Parkinson's over two years in 330 people, with and without a GBA gene change.
Who: People with Parkinson's in the UK, aiming for equal numbers with and without a GBA gene change. · Last checked 19 Oct 2026
Part of: Help cells clean up
Details and sources: ASPro-PD Check if it is recruiting: ASPro-PD
-
PARAISO · prasinezumab, an antibody drug
Result due Jun 2029
The main answer. It will show whether prasinezumab slows Parkinson's over at least 2 years.
Who: About 900 people with Parkinson's · Last checked 18 Oct 2026
Part of: Clear the bad protein
Details and sources: PARAISO Check if it is recruiting: PARAISO
-
ALN-SNCA · a drug that makes cells produce less of the protein
Result due Jun 2029
The first safety test in people with early Parkinson's.
Who: People with early Parkinson's · Last checked 19 Oct 2026
Part of: Clear the bad protein
Details and sources: ALN-SNCA Check if it is recruiting: ALN-SNCA
-
PRISMS · adalimumab, an antibody drug that calms inflammation
Result due Aug 2029
Tests whether calming inflammation can hold off Parkinson's in people with a sleep disorder that often comes first. It measures a brain-scan pattern, so it cannot prove that Parkinson's was prevented.
Who: Adults with REM sleep behaviour disorder, at sites in the US and Canada. · Last checked 18 Oct 2026
Part of: Preventing Parkinson's in people at risk
Details and sources: PRISMS Check if it is recruiting: PRISMS
Expected in 2030
2 trialsLY3962681, PreCoDe
-
LY3962681 · a drug that makes cells produce less of the protein
Result due Jul 2030
A safety test. People with Parkinson's must first have a positive spinal-fluid test for the protein.
Who: Healthy volunteers, and people with Parkinson's who test positive for the protein · Last checked 19 Oct 2026
Part of: Clear the bad protein
Details and sources: LY3962681 Check if it is recruiting: LY3962681
-
PreCoDe · prasinezumab, an antibody drug
Result due Dec 2030
Tests whether the drug slows memory and thinking problems in people with a GBA gene change. Not yet started.
Who: People with Parkinson's and a GBA gene change · Last checked 22 Oct 2026
Part of: Clear the bad protein
Details and sources: PreCoDe Check if it is recruiting: PreCoDe
Why dates slip
The dates here are the ones the trial teams give. They are expected, not promised. Trials often report late.
Finding enough people to take part can take longer than planned. After the last person finishes, the results take months to check. Some are first shared at a meeting and only later in a journal.
When a date passes with no result, we mark it as overdue. We check the trial registries each month and update this page.
Can I take part?
Some of these trials are still looking for people. Follow "Check if it is recruiting" on a trial to see its entry in the public trial register. Your neurologist or Parkinson's nurse can tell you whether a trial might suit you.